α- and γ-interferon versus α-interferon alone in chronic hepatitis B

Carréño, Vicente; Moreno, Alberto; Galiana, Fernando; Bartolomé, Fernando Javier

doi:10.1016/s0168-8278(05)80212-0

Cited by 17 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient had a significant elevation in aminotransferase levels, which led to cessation of therapy, after which aminotransferases normalized. Similar elevations in aminotransferases were observed in previous studies in patients with HBV infection who were treated with interferon gamma [34][35][36][37]. No episodes of acute liver failure have been reported with interferon gamma.…”

Section: Discussionsupporting

confidence: 86%

Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection

Muir

Sylvestre

Rockey

2006

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Given that the complications of hepatitis C are due to fibrosis, we hypothesized that the antifibrotic effects of interferon gamma on stellate cells would lead to beneficial effects in patients with hepatitis C. Thus, we evaluated the safety and efficacy of interferon gamma-1b in patients with hepatitis C. A cohort of 20 patients with chronic hepatitis C who failed or were intolerant to previous interferon-alpha-based regimens received 200 mug of interferon gamma-1b subcutaneously three times weekly for 24 weeks. Liver biopsy was performed prior to and at the end of treatment. Biopsies were evaluated by a single blinded pathologist using the Knodell system modified by Ishak, and fibrosis was also quantitated by morphometric analysis. The study population was 75% male and 70% Caucasian. Mean age was 47.9 +/- 7.5 years. Eighteen of 20 patients completed therapy. One patient discontinued therapy because of constitutional symptoms. One patient discontinued therapy because of elevated aminotransferases greater than twice baseline. No serious adverse events occurred. Morphometric analysis revealed that six patients (30%) had >1% absolute reduction in fibrosis score. Four of 20 (20%) patients had improvement in Ishak fibrosis scores after treatment. In conclusion, interferon gamma therapy is safe and well tolerated in patients with chronic hepatitis C. Although we did not detect an overall reduction in fibrosis, interferon gamma-1b treatment led to a reduction in fibrosis in selected patients. These data provide a basis for further study of interferon gamma-1b in patients with chronic fibrosing liver disease.

show abstract

Section: Discussionsupporting

confidence: 86%

Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection

Muir

Sylvestre

Rockey

2006

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…A number of studies have been published on the safety and antiviral efficacy of interferon-γ in patients with chronic viral hepatitis B where the combination of interferon-γ glus interferon-α or -β was evaluated (7)(8)(9). No significant, unexpected adverse events were noted; there was an acceptable safety and tolerability profile in this group of patients.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy

et al. 2006

View full text Add to dashboard Cite

Despite major advances in therapy of hepatitis C over the past decade, nearly half of the patients treated with the currently available regimens do not clear the virus. Therefore, there is a large unmet need for more effective therapy for patients who have failed pegylated interferon plus ribavirin therapy. We describe a case of a HCV genotype 1b patient who had failed previous combination therapies of interferon plus ribavirin and pegylated interferon plus ribavirin and was subsequently successfully treated with a novel triple drug combination consisting of interferon-gamma plus interferon alfacon plus ribavirin with the outcome of a sustained virologic response. This triple drug therapy combination could be an option for patients who have failed therapies with currently available pegylated interferons plus ribavirin. Prospective randomized studies are required to evaluate the effectiveness and tolerability of this regimen in this patient population.

show abstract

“…In parallel to its HBV antiviral activity, it has been reported that in cells constitutively expressing HBV, IFN-γ selectively inhibits HBV-mediated nuclear factor-κB activation through the nuclear localization of nuclear factor-κB-inducing kinase [13]. IFN-γ has been used in a series of studies to treat HBV infections, either alone or in combination with other IFNs and with varying success [19][20][21][22].…”

Section: Inhibition Of Hepatitis B Virus Dna Replication By a Thermosmentioning

confidence: 99%

Inhibition of hepatitis B virus DNA replication by a thermostable interferon-γ variant

et al. 2010

View full text Add to dashboard Cite

show abstract

α- and γ-interferon versus α-interferon alone in chronic hepatitis B

Cited by 17 publications

References 15 publications

Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection

Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection

Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy

Inhibition of hepatitis B virus DNA replication by a thermostable interferon-γ variant

Contact Info

Product

Resources

About